Quantification of Cerebral Blood Flow as Biomarker of Drug Effect: Arterial Spin Labeling phMRI After a Single Dose of Oral Citalopram

Arterial spin labeling (ASL) allows noninvasive quantification of cerebral blood flow (CBF), which can be used as a biomarker of drug effects in pharmacological magnetic resonance imaging (phMRI). In a double‐blind, placebo‐controlled crossover study, we investigated the effects of a single oral dose of citalopram (20 mg) on resting CBF in 12 healthy subjects, using ASL phMRI. Support‐vector machine (SVM) analysis detected significant drug‐induced reduction in CBF in brain regions including the amygdala, fusiform gyrus, insula, and orbitofrontal cortex. These regions have been shown to have abnormally elevated CBF in patients with major depression, as well as in subjects genetically prone to depression. Mixed‐effects analysis on data extracted from selected regions of interest (ROIs) revealed significant drug effect only in serotonergic areas of the brain (z = −4.45, P < 0.005). These results demonstrate the utility of ASL phMRI as a biomarker of pharmacological activity of orally administered drugs in the brain.

[1]  R. Buxton,et al.  Quantitative imaging of perfusion using a single subtraction (QUIPSS and QUIPSS II) , 1998 .

[2]  Siegfried Kasper,et al.  Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study , 2010, NeuroImage.

[3]  M E Raichle,et al.  Correlation Between Regional Cerebral Blood Flow and Oxidative Metabolism: In Vivo Studies in Man , 1976 .

[4]  T. L. Davis,et al.  Mr perfusion studies with t1‐weighted echo planar imaging , 1995, Magnetic resonance in medicine.

[5]  Seong-Gi Kim Quantification of relative cerebral blood flow change by flow‐sensitive alternating inversion recovery (FAIR) technique: Application to functional mapping , 1995, Magnetic resonance in medicine.

[6]  J. Mugler,et al.  Three‐dimensional magnetization‐prepared rapid gradient‐echo imaging (3D MP RAGE) , 1990, Magnetic resonance in medicine.

[7]  Herbert Feistel,et al.  Effects of sleep deprivation on the limbic system and the frontal lobes in affective disorders: A study with Tc-99m-HMPAO SPECT , 1991, Psychiatry Research: Neuroimaging.

[8]  P E Roland,et al.  Does mental activity change the oxidative metabolism of the brain? , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  Uwe Herwig,et al.  Serotonergic and Noradrenergic Modulation of Emotion Processing by Single Dose Antidepressants , 2010, Neuropsychopharmacology.

[10]  M. Raichle,et al.  A functional anatomical study of unipolar depression , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  W. Drevets Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders , 2001, Current Opinion in Neurobiology.

[12]  André Luxen,et al.  Frontal and parietal metabolic disturbances in unipolar depression , 1994, Biological Psychiatry.

[13]  L. Price,et al.  Acute changes in Cerebrospinal Fluid 5-HIAA following Oral Paroxetine Challenge in Healthy Humans , 2003, Neuropsychopharmacology.

[14]  J. Detre,et al.  A theoretical and experimental investigation of the tagging efficiency of pseudocontinuous arterial spin labeling , 2007, Magnetic resonance in medicine.

[15]  W. Drevets Neuroimaging studies of mood disorders , 2000, Biological Psychiatry.

[16]  Catherine J. Harmer,et al.  Effect of a single dose of citalopram on amygdala response to emotional faces , 2009, British Journal of Psychiatry.

[17]  D. Alsop,et al.  Continuous flow‐driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields , 2008, Magnetic resonance in medicine.

[18]  Rebecca Elliott,et al.  Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study , 2007, Neuroreport.

[19]  Guy M. Goodwin,et al.  Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues , 2006, Biological Psychiatry.

[20]  D. Altman,et al.  Measurement error. , 1996, BMJ.

[21]  B. Harrison,et al.  Influence of the fusiform gyrus on amygdala response to emotional faces in the non-clinical range of social anxiety , 2009, Psychological Medicine.

[22]  Chris Rorden,et al.  Improving Lesion-Symptom Mapping , 2007, Journal of Cognitive Neuroscience.

[23]  L. D. van de Kar,et al.  Selective serotonin reuptake inhibitors and neuroendocrine function. , 1999, Life sciences.

[24]  P. Netter,et al.  Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. , 2002, The international journal of neuropsychopharmacology.

[25]  C. Halldin,et al.  Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain , 2004, Human brain mapping.

[26]  P. Cowen,et al.  A single dose of citalopram increases fear recognition in healthy subjects , 2007, Journal of psychopharmacology.

[27]  E. Wong Quantifying CBF with pulsed ASL: Technical and pulse sequence factors , 2005, Journal of magnetic resonance imaging : JMRI.

[28]  P. Cowen,et al.  Comparison of the Effects of Citalopram and Escitalopram on 5-Ht-Mediated Neuroendocrine Responses , 2004, Neuropsychopharmacology.

[29]  John D Pickard,et al.  Intersubject Variability and Reproducibility of 15O PET Studies , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  J. Detre,et al.  Arterial spin labeling perfusion fMRI with very low task frequency , 2003, Magnetic resonance in medicine.

[31]  R. Elliott,et al.  Neuronal effects of acute citalopram detected by pharmacoMRI , 2005, Psychopharmacology.

[32]  L. Sokoloff,et al.  Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. , 1981, Federation proceedings.

[33]  J. Detre,et al.  Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. , 1999, European journal of radiology.

[34]  K. Bogeso,et al.  Escitalopram versus citalopram: the surprising role of the R-enantiomer , 2004, Psychopharmacology.

[35]  Joseph A Maldjian,et al.  Arterial transit time imaging with flow encoding arterial spin tagging (FEAST) , 2003, Magnetic resonance in medicine.

[36]  P. Cowen,et al.  Short-term antidepressant treatment modulates amygdala response to happy faces , 2009, Psychopharmacology.

[37]  M. Raichle,et al.  Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism , 2002, European Neuropsychopharmacology.

[38]  John A. Detre,et al.  Support vector machine learning-based fMRI data group analysis , 2007, NeuroImage.

[39]  C. Sánchez,et al.  R‐citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter , 2004, British journal of pharmacology.

[40]  F. Larsen,et al.  The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects , 2005, Journal of clinical pharmacology.

[41]  David C. Alsop,et al.  Increased cerebral perfusion in adult attention deficit hyperactivity disorder is normalised by stimulant treatment: A non-invasive MRI pilot study , 2008, NeuroImage.

[42]  Matthias J. Müller,et al.  Neuroendocrine Effects of a 20-mg Citalopram Infusion in Healthy Males , 1996, Neuropsychopharmacology.

[43]  A. Simmons,et al.  Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. , 2009, The international journal of neuropsychopharmacology.

[44]  John A. Detre,et al.  Genetic Variation in Serotonin Transporter Alters Resting Brain Function in Healthy Individuals , 2007, Biological Psychiatry.